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Abstract
Pheochromocytomas are rare chromaffin cell tumors that nevertheless
must be excluded in large numbers of patients who develop sustained
or episodic hypertension as well as in many others with suggestive
symptoms or with a familial history of pheochromocytoma. Diagnosis
of pheochromocytoma depends importantly on biochemical evidence
of excess catecholamine production by a tumor. Imperfect sensitivity
and specificity of commonly available biochemical tests and the low
incidence of the tumor among the tested population mean that consid-
erable time and effort can be expended in confirming or ruling out
pheochromocytoma in patients where the tumor is suspected. Meas-
urements of plasma free metanephrines provide a superior test com-
pared to other available tests for diagnosis of pheochromocytoma. In
particular, the high sensitivity of plasma free metanephrines means
that a normal test result reliably excludes all but the smallest of
pheochromocytomas so that no other tests are necessary. Measure-
ments of plasma free metanephrines, when systematically combined
with other diagnostic procedures outlined in this review, provide a
more efficient, reliable and cost-effective approach for diagnosis of
pheochromocytoma than offered by previously available approaches.
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Introduction
Pheochromocytomas are chromaffin cell
tumors typically arising within the adrenal
medulla. These tumors are a rare cause of
hypertension that nevertheless must be ex-
cluded in a significant proportion of the 20%
of the adult population of western countries
who develop high blood pressure. In the
United States alone this amounts to about
800,000 cases of newly diagnosed hyperten-
sion each year in which pheochromocytoma
may represent a correctable cause of high
blood pressure. In reality, however, it is not
feasible or cost effective to screen for pheo-
chromocytoma in every patient with hyper-
tension, particularly when commonly avail-
able tests do not always detect the tumor.
Therefore, this diagnosis is most often only
considered when a patient shows episodic
hypertension, fails to respond to antihyper-
tensive therapy, has a hypertensive episode
during anesthesia or surgery or when there
are other suggestive symptoms, such as head-
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ache, sweatiness, anxiety, palpitations or
tachycardia. It also must be considered
that some patients, particularly those with
a familial predisposition to pheochromocy-
toma, may not show increased blood pres-
sure or the typical symptoms of a pheo-
chromocytoma. In these patients biochemi-
cal diagnosis of the tumor can be particu-
larly troublesome.
Diagnosis of pheochromocytoma typi-
cally requires confirmation by several tests,
perhaps the most important being biochemi-
cal evidence of excessive catecholamine pro-
duction by the tumor. This is usually achieved
from measurements of catecholamines and
certain catecholamine metabolites in urine
or plasma (Table 1). However, the catechola-
mines, norepinephrine and epinephrine, are
also produced by sympathetic nerves and the
adrenal medulla and are thus not specific to
pheochromocytomas. Therefore, high levels
of catecholamines and their metabolites may
be produced by a variety of conditions or
disease states involving increased release of
catecholamines from sympathetic nerves or
the adrenal medulla (1). Sometimes pheo-
chromocytomas may be silent, that is they
may not produce catecholamines in amounts
sufficient to produce a positive biochemical
test result or the associated typical clinical
signs and symptoms. Also, many pheochro-
mocytomas secrete catecholamines episodi-
cally; between episodes, plasma concentra-
tions or urinary excretion of catecholamines
may be normal. Thus, tests of plasma or
urinary catecholamines and urinary metabo-
lites of catecholamines do not always reli-
ably exclude or confirm the presence of a
tumor (2-7). A more recently developed bio-
chemical test involving measurements of
Table 1 - Biochemical tests for diagnosis of pheochromocytoma.
Reference ranges indicate lower and upper reference limits of a normal population commonly estimated from
the 95% confidence intervals. Reference ranges vary among laboratories. VMA, Vanillylmandelic acid.
Biochemical test Measurement method Reference range
Urine catecholamines HPLC
Norepinephrine 15-80 µg/day
Epinephrine 0-20 µg/day
Urine fractionated metanephrines HPLC
Normetanephrine-sulfate 44-540 µg/day
Metanephrine-sulfate 26-230 µg/day
(Sum of free plus sulfate-conjugated
metanephrine or normetanephrine)
Urine total metanephrines Spectrofluorimetry 0-1.2 mg/day
(Combined sums of free plus sulfate-conjugated
metanephrine and normetanephrine)
Urine VMA Spectrofluorimetry 0-7.9 mg/day
Plasma catecholamines HPLC
Norepinephrine 80-498 pg/ml
Epinephrine 4-83 pg/ml
Plasma free metanephrines HPLC
Normetanephrine 18-112 pg/ml
Metanephrine 12-61 pg/ml
Plasma deconjugated metanephrines HPLC
Normetanephrine-sulfate 610-3170 pg/ml
Metanephrine-sulfate 316-1706 pg/ml
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Figure 1 - Pathways of metabo-
lism of norepinephrine and epi-
nephrine. Enzymes responsible
for each pathway are indicated
by the arrowheads. The more
solid arrows indicate the more
major pathways of metabolism
while the dotted arrows indicate
pathways of negligible impor-
tance. Compounds that are rou-
tinely measured in urine or plas-
ma for diagnosis of pheochro-
mocytoma are underlined. All
compounds except VMA are sul-
fate conjugated but only path-
ways of sulfate conjugation for
normetanephrine and metaneph-
rine are shown. PNMT, Phenol-
ethanolamine-N-methyltrans-
ferase; MAO, monoamine oxi-
dase; COMT, catechol-O-methyl-
transferase; ADH, alcohol dehy-
drogenase; m-PST, monoamine
preferring phenolsulfotransfer-
ase; DHPG, 3,4-dihydroxyphen-
ylglycol; DHMA, 3,4-dihydroxy-
mandelic acid; MHPG, 3-meth-
oxy-4-hydroxyphenylglycol; VMA,
vanillylmandelic acid.
plasma free normetanephrine and metaneph-
rine, the respective metabolites of norepi-
nephrine and epinephrine, offers advantages
over other tests for diagnosis of pheochro-
mocytoma (5,7). As reviewed here, the test
may offer a cost-effective approach for more
effective screening for the tumor than pro-
vided by other tests.
Disposition of catecholamines
derived from the sympatho-adrenal
system and pheochromocytomas
Understanding the utility and limitations
of biochemical tests for diagnosis of pheo-
chromocytoma can benefit from an under-
standing of catecholamine release and me-
tabolism under normal conditions as well as
in disease states associated with elevated
catecholamine release. Both norepinephrine
and epinephrine are metabolized by a multi-
plicity of pathways catalyzed by an array of
enzymes, resulting in a considerable number
of different metabolites, only some of which
are routinely used for diagnosis of pheochro-
mocytoma (Figure 1).
Most important to an understanding of
the utility of catecholamines and their me-
tabolites in the diagnosis of pheochromocy-
toma is an appreciation of how catechola-
mines are metabolized differently within
nerves and other cells, before and after their
entry into the bloodstream and among vari-
ous organs and tissues, including chromaffin
cells and pheochromocytoma tumor cells.
Pheochromocytomas differ from sympathetic
nerves or central nervous system noradre-
nergic nerves but are similar to adrenomed-
ullary cells in that they secrete catechola-
mines directly into the bloodstream. In con-
trast, the norepinephrine formed or released
from sympathetic nerves acts and is metabo-
lized locally so that only a small proportion
escapes local removal and metabolism to
diffuse into the bloodstream (8-10) (Figure
2).
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Since norepinephrine is the predominant
catecholamine secreted by pheochromocy-
tomas, an understanding of its metabolism
after release and production within sympa-
thetic nerves, as compared with after release
directly into the bloodstream by a pheochro-
mocytoma, is particularly important. Com-
parison of removal and metabolism of cat-
echolamines by neuronal and extraneuronal
cells has indicated that the sympathetic nerves
are far more important than the non-neu-
ronal cells for inactivation of neuronally re-
leased norepinephrine (9,10). This means
that most of the norepinephrine produced
and released by nerves is metabolized within
the nerves themselves (Figure 2). Because
monoamine oxidase (MAO) is the only cate-
cholamine-metabolizing enzyme present in
sympathetic nerves, the norepinephrine me-
tabolized within these nerves is all converted
to dihydroxyphenylglycol (DHPG) (11-13).
As a consequence, the DHPG appearing in
Figure 2 - Quantitative diagram showing neuronal and extraneuronal pathways of norepinephrine (NE) metabolism
before and after entry into the bloodstream. Numbers indicated by arrowheads show relative rates of each process
as derived from previously published data. The diagram does not show sulfate conjugation pathways of metabo-
lism that are particularly important for normetanephrine (NMN) and 3-methoxy-4-hydroxyphenylglycol (MHPG). The
diagram also does not include the contribution of the adrenals to circulating NE (9%) and free NMN (24-40%). Most
of the NE released by sympathetic nerves (a) is removed by neuronal uptake (b) and a much smaller amount is
removed by extraneuronal uptake (c) so that only a small portion escapes to enter the bloodstream (d). Most of the
NE recaptured by sympathetic nerves is sequestered into storage vesicles by the vesicular monoamine oxidase
(MAO) transporter (f) and a smaller proportion is metabolized intraneuronally to 3,4-dihydroxyphenylglycol (DHPG).
However, considerably more of the NE that is sequestered into storage vesicles or metabolized intraneuronally to
DHPG is derived from transmitter leaking from storage vesicles (e) than from reuptake (b). Very little circulating
DHPG is derived from metabolism of circulating NE, whereas a significant proportion of the small amounts of
circulating free NMN is formed from circulating NE. MHPG is mainly derived from O-methylation of DHPG before
and after its entry into the bloodstream. Vanillylmandelic acid (VMA) is mainly derived from metabolism of MHPG
and DHPG in the liver. COMT, Catechol-O-methyltransferase.
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plasma is almost exclusively produced in
sympathetic nerves, whereas the additional
presence of catechol-O-methyltransferase in
extraneuronal cells means that normetaneph-
rine is exclusively produced from norepi-
nephrine in extraneuronal cells, such as
smooth muscle cells or liver cells (9,11).
Much of the DHPG formed in nerves is
metabolized further to 3-methoxy-4-hydroxy-
phenylglycol (MHPG) by catechol-O-meth-
yltransferase in extraneuronal cells (14).
The above considerations combined with
the series nature of neuronal and extraneuro-
nal removal and metabolism (15) explain
why very little of the DHPG in plasma (<1%)
is derived from neuronal metabolism of nor-
epinephrine released directly into the blood-
stream (Figure 2). Thus, release of norepi-
nephrine from a pheochromocytoma directly
into the bloodstream causes only small in-
creases in DHPG compared with release of
norepinephrine from nerves (16). Hence, pa-
tients with pheochromocytoma and high nor-
epinephrine levels often have normal or only
slightly elevated plasma concentrations of
DHPG (16,17). Findings of a high norepi-
nephrine combined with a normal DHPG
therefore provide supportive evidence that
an increased plasma concentration of nor-
epinephrine is not due to excessive release
from sympathetic nerves and might rather
reflect a tumor (16,18,19).
Vanillylmandelic acid (VMA), the major
end-product of norepinephrine and epineph-
rine metabolism, is produced almost exclu-
sively from the removal and metabolism by
the liver of catecholamines and their me-
tabolites that circulate in the bloodstream
(20) (Figure 2). This is because the enzyme
responsible for formation of VMA from
MHPG, alcohol dehydrogenase, is localized
to the liver (21,22). The substantial produc-
tion of VMA from circulating DHPG and
MHPG, most of which is derived from neu-
ronal norepinephrine metabolism, explains
why VMA is a relatively insensitive marker
for pheochromocytoma compared with the
precursors norepinephrine, epinephrine, nor-
metanephrine and metanephrine (23-27).
Normally at least 90% of metanephrine
and up to 40% of normetanephrine are formed
from metabolism of epinephrine and norepi-
nephrine within the adrenals before release
of these catecholamines into the circulation
(28,29). This makes the adrenal medulla the
single largest source of both normetaneph-
rine and metanephrine in the body, exceed-
ing the contribution of the liver (28). Both
adrenomedullary and pheochromocytoma tu-
mor cells contain high quantities of catechol-
O-methyltransferase (30), the enzyme that is
responsible for O-methylation of catechola-
mines to form normetanephrine and meta-
nephrine (31). The catechol-O-methyltrans-
ferase is localized within chromaffin cells so
that the normetanephrine and metanephrine
from these sources are derived from cat-
echolamines leaking from stores into the
chromaffin cell cytoplasm.
In patients with pheochromocytoma, over
94% of the elevated plasma concentrations
of normetanephrine or metanephrine are de-
rived from metabolism of catecholamines by
the catechol-O-methyltransferase within
pheochromocytoma tumor cells and not by
actions of extra-adrenal catechol-O-methyl-
transferase on catecholamines released by
tumors into the circulation (30). This means
that production of normetanephrine and me-
tanephrine is an ongoing process within pheo-
chromocytoma tumor cells, independent of
catecholamine release. This explains why
plasma concentrations of normetanephrine
and metanephrine are relatively insensitive
markers of increased norepinephrine release
by nerves or increased epinephrine release
from the adrenals or of a paroxysmal attack
associated with large increases in catechola-
mine release from a pheochromocytoma (30).
However, this also means that even when
tumors are not secreting catecholamines into
the bloodstream they are nevertheless con-
stantly metabolizing catecholamines to nor-
metanephrine and/or metanephrine.
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Sensitivity of biochemical tests
The sensitivity of a test for diagnosis of
pheochromocytoma is indicated by the pro-
portion of patients with a tumor who have a
positive test result (i.e., an elevated plasma
concentration or urinary output). A sensitiv-
ity of 100% indicates that in all cases of
patients who have a tumor the test will be
positive. A sensitivity of 100% also means
that a normal test result reliably excludes the
presence of a tumor. Importantly, it must be
realized that a high sensitivity of 100% does
not necessarily prove the existence of a pheo-
chromocytoma in all patients who have a
positive test result. This depends on the speci-
ficity of the test.
A problem with use of plasma or urinary
catecholamines for diagnosis of pheochro-
mocytoma is that some tumors are quiescent
and may not secrete large amounts of cat-
echolamines while other tumors secrete cat-
echolamines episodically. Thus, plasma lev-
els and urinary outputs of catecholamines
are normal in some patients with pheochro-
mocytoma and the presence of a pheochro-
mocytoma cannot be reliably excluded using
measurements of plasma or urinary catecho-
lamine concentrations (2-7,23-27). In con-
trast, the metanephrines (either normetaneph-
rine or metanephrine or both) are constantly
produced by the actions of catechol-O-meth-
yltransferase on catecholamines leaking from
stores within tumor cells and therefore show
much more consistent increases above nor-
mal in patients with pheochromocytoma than
plasma catecholamines (5,7) (Figure 3). This
means that measurements of plasma nor-
metanephrine and metanephrine reliably ex-
clude the presence of all but the smallest of
pheochromocytomas. Where excluded, no
other tests are necessary. Thus, measure-
ments of plasma metanephrines avoid a
missed diagnosis and minimize the need to
run multiple diagnostic tests to exclude the
presence of a tumor. This also means that a
Figure 3 - Plasma concentrations
of normetanephrine, metaneph-
rine, norepinephrine and epi-
nephrine in 29 patients with von
Hippel-Lindau (VHL) disease and
pheochromocytoma (grey bars)
and 10 patients with multiple
endocrine neoplasia type 2
(MEN-2) and pheochromocy-
toma (black bars). Each bar rep-
resents a concentration of one
of the 4 analytes for a single pa-
tient. The lower dashed lines
show the upper reference limits
(URL) of normal levels. Concen-
trations above these lines are
high and those below are nor-
mal. The upper dashed lines
show levels at 5 times the upper
reference limits. Concentrations
above the horizontal lines almost
certainly indicate the presence
of a pheochromocytoma.
1163
Braz J Med Biol Res 33(10) 2000
Plasma metanephrines and pheochromocytoma
person with normal plasma concentrations
of normetanephrine and metanephrine can
be fairly confident of not having a pheochro-
mocytoma.
Since the free metanephrines are formed
extraneuronally, and to a large extent within
chromaffin tissues (e.g., adrenal medulla and
pheochromocytomas), these metabolites are
also more sensitive markers for a pheochro-
mocytoma than the other catecholamine
metabolites that are derived mainly from
neuronal sources.
Urinary metanephrines are commonly
measured after acid hydrolysis and thus
largely represent sulfate-conjugated normeta-
nephrine and metanephrine. A substantial
amount of the normetanephrine-sulfate is
derived from sulfate conjugation of normeta-
nephrine produced in parts of the body other
than the adrenal medulla or pheochromocy-
toma tumor chromaffin tissue. Therefore,
the sulfate-conjugated normetanephrine, as
commonly measured in urine, is a less sensi-
tive marker of pheochromocytoma than the
free normetanephrine measured in plasma.
In particular, measurements of the combined
sum of urinary outputs of normetanephrine
and metanephrine in sulfate-conjugated plus
free form (commonly known as urinary total
metanephrines), as measured by outdated
spectrofluorometric methods, are not sensi-
tive tests of a pheochromocytoma; therefore,
they have limited value in the initial work-up
of a patient suspected of having a pheochro-
mocytoma. The low sensitivity of urinary
VMA also makes this test less than satisfac-
tory for the initial biochemical diagnosis of a
pheochromocytoma.
Specificity of biochemical tests
As distinct from sensitivity, the specific-
ity of a biochemical test indicates how likely
it is that a patient with a positive test result
has a pheochromocytoma. Thus, a high speci-
ficity of 100% would indicate that the test
reliably proves the presence of a pheochro-
mocytoma in all patients with a positive test
result. Importantly, it must be realized that a
high specificity of 100% does not necessar-
ily mean that all patients with a pheochro-
mocytoma will have a positive test result.
This is a matter of sensitivity.
Since upper reference limits of normal of
most diagnostic tests are typically established
from the 95% confidence intervals (with
2.5% below and 2.5% above) of a range of
values determined in a reference population
(see Table 1 for normal reference limits), it
can be expected that all tests will give at least
a 2.5% incidence of false-positive results
(i.e., 2.5% of all test results will show an
elevated value that might suggest the pres-
ence of a tumor when none is really present).
This means that no biochemical test can be
expected to have 100% specificity and the
best that might be expected would be 97.5%.
In practice, however, because many of the
patients screened for pheochromocytoma are
ill and may have activated sympatho-adre-
nomedullary systems, the specificity of tests
of catecholamines and metabolites is often
lower than 97.5%.
Since the catecholamines and their me-
tabolites are normally produced by sympa-
thetic nerves and the adrenal medulla, none
of these compounds are highly specific for
the presence of a pheochromocytoma. In
particular, plasma and urinary catechola-
mines may be elevated by a variety of physi-
ological, pharmacological and pathological
conditions (1). Nevertheless, the combina-
tion of measurements of catecholamines
and of certain metabolites can be useful in
helping to distinguish elevated catechola-
mines due to a tumor from elevated cat-
echolamines secondary to increased release
from sympathetic nerves or the adrenal me-
dulla.
Increased release of catecholamines from
sympathetic nerves or the adrenal gland sec-
ondary to exercise, mental stress, low blood
pressure, low blood volume, low blood glu-
cose or certain drugs represent conditions
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that may elevate plasma and urinary cat-
echolamines and cause false-positive test
results. During blood sampling and 24-h urine
collections these influences must be avoided.
Upright posture is another important deter-
minant of catecholamine release, increasing
plasma norepinephrine by as much as 3-fold
above values in the lying position. There-
fore, collection of blood samples should be
performed with the patient resting quietly in
the lying position for at least 20 min before
sampling with an indwelling intravenous
catheter previously inserted to avoid any
possible acute stress associated with inser-
tion of the needle.
A wide variety of pathological conditions
may be associated with elevated plasma and
urinary catecholamines. Congestive heart fail-
ure, renovascular hypertension, hypernorad-
renergic hypertension, shock, sepsis, dumping
syndrome, sleep apnea, anxiety neurosis and
panic disorder are some of the syndromes that
may be associated with elevated plasma or
urinary catecholamines and clinical symptoms
suggestive of a pheochromocytoma.
The above physiological and pathologi-
cal conditions can also lead to elevated pro-
duction of metanephrines and VMA, with
attendant false-positive test results for these
metabolites. However, because production
of these metabolites is somewhat independ-
ent of catecholamine release from the sym-
pathetic nerves or the adrenal medulla, their
proportional increases are typically less than
those in catecholamines. The metanephrines,
in particular, are relatively poor markers of
increased release of catecholamines from
sympathetic nerves or the adrenal gland
(29,30). Theoretically, this should make the
metanephrines less prone to false-positive
results in physiological and pathological
states associated with sympatho-adrenomed-
ullary activation. However, there are other
factors to consider that may additionally con-
tribute to false-positive results for these tests.
Deficiency or pharmacological inhibition of
MAO increases both urinary deconjugated
and plasma free metanephrines due to im-
paired breakdown of the metabolite by MAO
and increased shunting of metabolism
through O-methylation pathways (32,33).
Severe renal failure can be particularly prob-
lematic in patients suspected of having a
pheochromocytoma, making urine test re-
sults unreliable (34) or urine collection im-
possible. In these patients biochemical diag-
nosis typically requires assays of plasma
catecholamines and metanephrines. How-
ever, the sympathetic nerves can be acti-
vated in these patients, resulting in elevated
plasma norepinephrine concentrations. Also,
end-products of catecholamine metabolism,
that depend on elimination by the kidneys -
such as the sulfate-conjugated metanephrines
- tend to build up in plasma to very high
levels (35).
During interpretation of biochemical test
results it is important to keep in mind that
these are numerical values and should not be
considered as simply either negative (within
the normal range) or positive (above the
normal range). Rather, the magnitude of an
increase above normal values should also be
considered. For example, a patient present-
ing with suggestive symptoms and a plasma
norepinephrine concentration of over 2500
pg/ml (14.8 pmol/ml), approximately 5 times
above the upper reference limit of normal, is
far more likely to have a pheochromocytoma
than a patient with the same symptoms and a
plasma norepinephrine concentration just
above the upper reference limits. The few
conditions where plasma norepinephrine can
reach such high levels (e.g., hypernoradre-
nergic hypertension, end-stage congestive
heart failure, circulatory shock) are easily
excluded. In patients with pheochromocy-
toma, plasma concentrations of normetaneph-
rine and metanephrine typically show much
larger relative increases above the upper ref-
erence limits than observed for tests of cat-
echolamines, urinary metanephrines and
VMA. This indicates that at the higher limits
more specific for a tumor, measurements of
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plasma normetanephrine and metanephrine
provide better proof (i.e., are more specific)
of a pheochromocytoma than other available
tests.
Diagnostic procedural
recommendations
Initial biochemical testing
With issues of sensitivity and specificity
in mind, as well as consideration of the
potential dangers of a pheochromocytoma
and the rarity of the tumor, the most impor-
tant consideration in the choice of an initial
biochemical test is the reliability of the test
for exclusion of pheochromocytoma. In pheo-
chromocytoma, a missed diagnosis due to a
false-negative test result can have cata-
strophic consequences for the patient. In
contrast, a single false-positive test result
can be refuted by further tests. Therefore, a
suitably sensitive biochemical test remains
the first choice in the initial work-up of the
patient suspected to be harboring a pheo-
chromocytoma. With most available bio-
chemical tests, however, confirming the ab-
sence of a tumor can be more problematic
than confirming the presence of a tumor.
Because of the high sensitivity of the test,
our recommendation is to use HPLC meas-
urements of plasma free normetanephrine
and metanephrine as the initial biochemical
test of choice. This test can be combined
with or followed by HPLC measurements of
plasma catecholamines collected under ap-
propriately controlled circumstances for fur-
ther interpretation of any elevations in plasma
free metanephrines. To circumvent false-
positive test results, appropriate consider-
ation should always be given to interference
with assay results by any drugs that the pa-
tient may be taking.
If plasma free metanephrines have been
run, and they are well within the normal
range, then it is highly unlikely that the
patient has anything but a very small tumor
(most likely less than 1 cm in diameter) and
there should be little need to run further tests
at this stage. On the other hand, normal
results for each of the other biochemical
tests, even when performed in combination,
are still possible in some patients with a
pheochromocytoma. Thus, if plasma free
metanephrines have not been run, but the
other above test results are all normal, then it
is still possible that the patient has a pheo-
chromocytoma.
Secondary diagnostic tests
If tests of plasma free metanephrines or
any of the above combinations of test results
are positive then further tests must be con-
sidered to exclude or prove the existence of
a pheochromocytoma. At this stage it is again
important to consider any potential associ-
ated clinical conditions or influences of medi-
cations that may cause a false-positive test
result. Additional considerations include the
magnitude of increase above normal of bio-
chemical test results (Figure 3) along with
the pattern of alterations in biochemical pa-
rameters which may be used together to
make some kind of qualitative assessment of
the likelihood that the patient has a tumor.
From this a strategy for further testing can be
developed, including imaging studies to lo-
calize the tumor, provocation tests and fur-
ther biochemical tests. Ultimately, it is a
combination of biochemical and radiologi-
cal tests combined with clinical assessment
of symptoms, signs and associated condi-
tions that provides the clinician with suffi-
cient evidence to establish or refute the diag-
nosis of pheochromocytoma.
Ruling out sympatho-adrenomedullary
activation
Use of the clonidine suppression test is
particularly useful when there is suspicion
that elevated plasma concentrations of nor-
epinephrine are secondary to increased re-
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lease of the transmitter from sympathetic
nerves rather than from a pheochromocy-
toma. The basis of the test is simple and
involves oral administration of the drug, clo-
nidine, with measurements of plasma nor-
epinephrine concentrations before and 3 h
after the drug. Clonidine acts on centers in
the brain to decrease the release of norepi-
nephrine from sympathetic nerve terminals.
The drug does not decrease release from a
pheochromocytoma. Thus, the drug will de-
crease elevated plasma norepinephrine con-
centrations in a patient whose elevations are
due to increased release of the transmitter
from sympathetic nerves; a pheochromocy-
toma may then be excluded. In a patient with
high plasma norepinephrine concentrations
due to release from a pheochromocytoma,
the norepinephrine concentrations are little
affected by clonidine.
Other indicators of sympatho-adrenomed-
ullary activation, rather than a pheochromocy-
toma, are the distinct patterns of biochemical
test results that accompany sympathetic acti-
vation as opposed to a tumor. Patterns of
biochemical test results that are more sugges-
tive of increased release from sympathetic
nerves or the adrenal gland than from a tumor
(such as occurs in hypernoradrenergic hyper-
tension, renovascular hypertension, conges-
tive heart failure, panic disorder, dumping
syndrome, and other conditions) include pro-
portionally larger elevations of plasma norepi-
nephrine or epinephrine than of plasma nor-
metanephrine or metanephrine. In sympathetic
activation, increases in plasma DHPG that
parallel the increases in norepinephrine typi-
cally reflect a source of the elevated norepi-
nephrine from sympathetic nerves rather than
from a pheochromocytoma. This pattern of
biochemical test results combined with a nega-
tive clonidine suppression test result (i.e., a
substantial decrease in plasma norepinephrine
after clonidine) is highly suggestive of sympa-
thetic activation rather than a tumor, and, un-
less imaging studies suggest otherwise, a pheo-
chromocytoma can be excluded and no further
tests should be necessary.
Locating the tumor
If plasma or urine levels of catechola-
mines and metanephrines are high, suppres-
sion tests and/or stimulation tests are posi-
tive (i.e., plasma norepinephrine does not
decrease after clonidine, plasma norepineph-
rine shows a substantial increase after gluca-
gon), or if the biochemical pattern of test
results is indicative of a tumor rather than
increased release from sympathetic nerves
or the adrenal gland, then it is important to
localize the tumor for subsequent surgical
removal.
In most cases of positive initial biochemi-
cal test results, where clinical suspicion of a
pheochromocytoma remains reasonable, a
CT or magnetic resonance imaging (MRI)
scan of the entire abdomen may be immedi-
ately appropriate. A finding of an adrenal or
abdominal mass together with suggestive
clinical signs and symptoms and highly el-
evated catecholamines and their metabolites
and an appropriate pattern of changes in
metabolites and catecholamine precursors
(i.e., larger relative increases in plasma free
metanephrines than catecholamines and/or
normal plasma DHPG levels) might be all
that is needed at this stage to justify surgery.
However, in many cases it is also appropri-
ate to follow up with MIBG scintigraphy -
preferably using the 123-iodine-labeled com-
pound rather than the 131-iodine-labeled
compound - to establish more reliably that a
located mass is a pheochromocytoma or to
locate an extra-adrenal tumor or metastases.
Identifying the “silent” pheochromocytoma
In occasional cases of sporadic pheo-
chromocytoma and in some incidentalomas,
but quite frequently during routine screening
of patients with von Hippel-Lindau (VHL)
disease or multiple endocrine neoplasia type
2 (MEN-2), a small adrenal mass may be
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present without any of the symptoms and
signs associated with a pheochromocytoma
(7,36,37). In these patients, the pheochro-
mocytoma is silent and may not produce
catecholamines in amounts sufficient to cause
typical symptoms or a positive test result for
plasma or urinary catecholamines, urinary
VMA or urinary metanephrines. These pa-
tients, however, typically show some eleva-
tion of either plasma free normetanephrine
(VHL patients) or both plasma free normeta-
nephrine and metanephrine or only meta-
nephrine (MEN-2 patients). Should this not
be sufficient reason to operate, then it is
important to follow these patients carefully
over time, since as the tumor(s) enlarge
plasma free normetanephrine and/or meta-
nephrine increases, providing a stronger rea-
son to operate. Use of glucagon-stimulation
tests and other imaging techniques with
higher specificity than CT, such as MIBG
scintigraphy, may also be useful to identify a
silent pheochromocytoma. However, the
likelihood of false-negative results for the
glucagon-stimulation test and MIBG scan-
ning, particularly in cases of small tumors,
points to the need for careful follow-up stud-
ies in patients suspected of harboring a si-
lent pheochromocytoma.
Summary: the cost-effectiveness of
plasma metanephrines
In the United States only about 10% and
perhaps as many as 20% of all newly diag-
nosed hypertensives are screened for pheo-
chromocytoma. Nevertheless, this represents
about 80,000 to 160,000 patients each year
who are tested. Testing is also often carried
out in normotensive individuals who com-
plain of other symptoms suggestive of a
pheochromocytoma (e.g., panic attacks).
Patients with familial conditions that predis-
pose to pheochromocytoma, such as mul-
tiple endocrine neoplasia type 2 and von
Hippel-Lindau disease, represent another
group in whom testing for the tumor is called
for on an annual basis. Thus, currently in the
United States alone somewhere between
100,000 and 200,000 individuals are screened
for the tumor every year. Of these only be-
tween 800 to 1600 patients are subsequently
found to have the tumor, representing an
incidence of the tumor in the tested popula-
tion of about 1 in 1000 cases. Because of the
limitations of commonly available tests many
other patients with pheochromocytoma are
never diagnosed and die prematurely as a
consequence of the clinical complications of
the tumor.
The cost-effective potential of plasma
metanephrines as the initial screening test
for detection of pheochromocytoma prima-
rily depends on the high sensitivity of the
test. This high sensitivity not only avoids the
potential catastrophic consequences to the
patient of a missed diagnosis but also means
that in a patient with a negative test result a
pheochromocytoma can be confidently ex-
cluded. By reliably excluding the presence
of pheochromocytoma when the test is nega-
tive, no further tests are necessary. This alone
would cut down on the current average of 3
to 4 tests performed on each patient to only 1
test per patient. At a cost of at least US$100
per test (including costs at the clinic of sample
collection as well as subsequent shipping
and additional charges associated with in-
surance) and with up to 200,000 individuals
screened for pheochromocytoma annually,
this represents a potential savings to the
United States health care system in unneces-
sary biochemical tests alone in excess of
US$50 million per year. A similar saving in
the form of costs of unnecessary and more
expensive CT, MRI and MIBG imaging stud-
ies could also be expected.
Of course, as with all biochemical tests, it
can be expected that of the 200,000 tests of
plasma metanephrines that would be required
each year, at least 5% would be positive,
with most of these representing false-posi-
tive test results. The incidence of false-posi-
tive test results can be expected to increase
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with each additional test that is carried out.
Thus, reducing the number of initial diag-
nostic tests to a single test of plasma meta-
nephrines can also be expected to lead to
reduction in subsequent costs when one of
the multiple tests is positive and further test-
ing, including expensive imaging studies, is
called for. Among the 10,000 positive test
results that might be expected for a single
test of plasma metanephrines (i.e., 5% of
200,000 tests), about 10% can be expected
to represent true-positive test results. Among
these, about 70% can be expected to have
plasma levels of metanephrines so high that
the test results could only reflect a pheochro-
mocytoma (i.e., as opposed to sympatho-
adrenomedullary activation). In these pa-
tients, the clinician can immediately concen-
trate on the task of locating the tumor with-
out the need for further biochemical tests.
Because other tests do not show the same
magnitude of increase associated with a pheo-
chromocytoma, these other tests do not reli-
ably prove the presence of the tumor in the
same high proportion of patients as tests of
plasma metanephrines. This can be expected
to result in further cost reductions.
With the above considerations in mind it
can be appreciated that tests of plasma
metanephrines would not only improve the
chances of survival for the patient with the
tumor, but would also lead to considerable
savings in costs for any health care system
where the test is appropriately implemented.
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